NKNatalia D. Karseladze

Natalia D. Karseladze

*This is an algorithmically generated author record based on publicly available information.

Natalia D. Karseladze has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic markers of cardiotoxicity associated with anticancer therapy

    by N. V. Orlova, L. I. Ilenko, N. D. Karseladze, M. V. Burak, O. A. Tiganova, K. M. Dyakova, M. A. Krivtsova, U. A. Burilina, M. V. Moroz, K. Yu. Samgurova, et al.

    The improvement in survival rates for most malignant neoplasms (MNOs) poses a challenge to healthcare in terms of longterm complications of antitumor chemotherapy (ATC). The clinical manifestations of ATC complications affecting various organs are nonspecific, which makes their diagnosis difficult, especially against the background of the course of the underlying MNO. The longterm consequences of ATC administered in childhood may manifest themselves years or even decades later. Doctors across a wide range of specialties need knowledge in the field of pharmacogenetics of chemotherapy drugs, as well as in the clinical manifestations of these drugs, including delayed ones, due to the possibility of adverse effects of chemotherapy on various organs and systems. Due to the use of cardiotoxic drugs in the treatment of malignant neoplasms in childhood, there is a risk of longterm adverse effects on the cardiovascular system.

  • Open Access

    Cardiotoxic effects of antitumor chemotherapy in the treatment of a patient with gastric adenocarcinoma

    by N. D. Karseladze, P. S. Sergeev, A. O. Mezhueva, V. A. Pirozhnikov

    Background. Fluoropyrimidines such as 5-fluorouracil and its oral prodrug capecitabine are widely used in treating gastrointestinal malignancies but are associated with potentially severe cardiotoxicity. Nephrotoxicity associated with platinum-based therapies (Cisplatin, Oxaliplatin). Case summary. We present the case of a 60-year-old man with resected gastric adenocarcinoma (T3N 2M0) treated with adjuvant FOLFOX (5-fluorouracil plus oxaliplatin). On the first day of the second cycle, he developed tachycardia. Electrocardiogram showed supraventricular tachycardia and on next day-atrial flutter, while echocardiography demonstrated reduced ejection fraction. Troponin I was 2.7. Chemotherapy was discontinued, and a reduced dose of capecitabine was recommended. Conclusions. This case illustrates the cardiotoxicity of oxaliplatin, with both supraventricular tachycardia and atrial flutter, while echocardiography demonstrated reduced ejection fraction.

  • Diseases of the urinary system in patients with acute lymphoblastic leukemia in childhood

    by N. V. Orlova, N. D. Karseladze, O. A. Tiganova, I. S. Pinchuk, S. S. Dogaeva, D. A. Rozanova, К. L. Kondratchik

    More than 80% of children have long-term survival after treatment for acute lymphoblastic leukemia. Antitumor treatment can lead to undesirable effects in the long term, including damage to the urinary system. Nephrotoxicity is an undesirable phenomenon of several types of treatment, including cisplatin, carboplatin, ifosfamide, and radiation therapy. A study of the health status of 100 patients who suffered from acute lymphoblastic leukemia in childhood, according to the EMIAS, revealed that 23 patients had never sought medical help or undergone examinations, 31% had diseases of the urinary system: 7 nephritis (22.6%), 5 urolithiasis (16.1%); cystitis – 13 (41.9%); nephritic syndrome – 4 (12.9%); chronic prostatitis – 2 (6.5%). An analysis of the incidence of urinary tract diseases in patients who had ALL in childhood, depending on the antitumor treatment performed, showed that the majority of cases (93.6%) were detected in patients with antitumor chemotherapy. The prevalence of diseases of the urinary system among adults who suffered from ALL in childhood requires a deeper study of the risks and the relationship of treatment with long-term adverse events. Clinical dynamic monitoring by a urologist of patients who suffered from acute lymphoblastic leukemia in childhood will allow timely detection of long-term adverse events from the urinary system, treatment and preventive measures.

  • Microcirculation disorders in hypertensive disorders in pregnant women

    by N. V. Orlova, L. I. Ilyenko, N. D. Karseladze, S. V. Goryainova, Yа. G. Spiryakina, Я. Г. Спирякина

    Arterial hypertension poses a threat to both the pregnant woman and the health of the newborn. Vascular disorders play an important role in the pathogenesis of hypertension. A study of microcirculation in arterial hypertension was conducted with the inclusion of 42 women with newly diagnosed or untreated arterial hypertension of grade 1–2 and a control group. Microcirculation was studied by capillaroscopy of the nail bed. The revealed changes in the microcirculatory system in women with arterial hypertension compared with patients without arterial hypertension included changes in the density of the capillary network in the form of rarefaction, degree of tortuosity, enlargement of the perivascular zone, arterial capillaries, venous capillaries, diameter of the transitional capillaries. The study of the prevalence of complications of pregnancy and childbirth in arterial hypertension of pregnant women, as well as its effect on the condition of the newborn. The analysis of 150 SMADS of pregnant women and information from EMIAS was carried out. The prevalence of hypertensive disorders among pregnant women was 19.3%. 69% of pregnant women with hypertension had this disease before pregnancy. An analysis of the complications of current pregnancy in hypertensive disorders showed a high percentage of the incidence of preeclampsia or a high risk of its development (41.38%). The incidence of preeclampsia and a high risk of its development in women without hypertension was 5.3%. Among the complications of pregnancy with hypertension, the following were identified: gestational diabetes mellitus – 31%, anemia of varying severity – 17.2%, gestational hypertension – 10.3%, toxicosis – 6.9%, threat of premature birth – 3.5%, gestational pyelonephritis – 3.5%. When assessing the relationship between hypertension and complications in childbirth, the following data were obtained: preterm birth – 16.7%, cesarean delivery – 47.4%, premature discharge of amniotic fluid/membranes – 21.1%, ruptures of the cervix/perineum – 21.1%, vacuum extraction of the fetus – 5.2%, fetal distress – 10.5%. the birth of children with a height of less than 45 cm and weighing less than 2500 g – 10.5%. The data we obtained coincided with the results of most studies that revealed a high risk of pregnancy and childbirth complications in pregnant women with hypertension. Prediction of arterial hypertension during pregnancy. it is an urgent task. Methods for studying microcirculation are available and can be used for screening surveillance to identify women at risk of hypertensive pregnancy complications at the planning stage.

  • Long-term effects of treatment of acute lymphoblastic leukemia in childhood on the part of the musculoskeletal system

    by N. D. Karseladze, N. V. Orlova, O. A. Tiganova, D. P. Sichinava, T. V. Nalegach

    Effective treatment of leukemia in children has improved both the five-year and long-term survival of patients. An increase in life expectancy requires an assessment of the long-term effects of treatment. The use of antitumor drugs such as mercaptopurin, methotrexate, tyrosine kinase inhibitors, as well as glucocorticosteroids often negatively affect the musculoskeletal system, including bone mineralization, which can lead to fractures, necrosis, arthropathy and other lesions of the musculoskeletal system, Side effects of anticancer drugs, glucocorticosteroids on bone tissue are especially important in childhood, when the skeleton is being formed and their long-term negative effect on the musculoskeletal system is no less important. The assessment of long-term consequences will make it possible to develop timely preventive measures. KEYWORDS: bone tissue, antitumor therapy, leukemia, long-term effects of treatment.

  • Open Access

    The possibilities of big data in pharmacoepidemiology, problems of use, legal regulation

    by N. V. Orlova, G. N. Suvorov, N. D. Karseladze, Yu. Yu. Yakushev, T. V. Gololobova, Ю. Ю. Якушев

    The growth of digitalization in medicine has significantly expanded the possibilities of using big data in pharmacoepidemiology. The use of big data makes it possible to reduce the cost of clinical research, increase the speed of recruitment and expand the sample, makes it possible to evaluate the effect of drugs in pregnant women and effectiveness in rare diseases. The databases PubMed, Scopus, Web of Science and Google Scholar for 12 years from 2012 to 2023, United Nations documents, World Health Organization, Federal laws of the Russian Federation in the field of artificial intelligence, protection of confidential information, and clinical research were analyzed. The search was carried out by keywords: «big data», «registers», «pharmacoepidemiology», «personal data», «legal regulation», «protection methods». The article provides examples of the use of big data in healthcare, including from 25 to 50 million people. The analysis of the literature data revealed the same type of problems – the lack of uniformity in the introduction of information, incomplete information, limited availability. The review identifies the problems of protecting the confidentiality of information. The mechanisms of information standardization, storage, and data processing are considered. The international and Russian legislative framework regulating the conduct of clinical trials using big data is presented.


  • Drug-induced agranulocytosis – prevalence, complications, management tactics

    by A. A. Pecherskikh, B. A. Chaparyan, N. V. Orlova, T. V. Pinchuk, E. S. Chernenok, N. D. Karseladze

    Based on the results of a review of clinical cases and research data, the prevalence of drug-induced agranulocytosis, complications and management tactics are considered. A clinical case of agranulocytosis caused by taking nonsteroidal anti-inflammatory drugs (NSAIDs) is presented. The patient was admitted to the purulent surgical department with purulent lymphadenitis and sepsis. During the examination, agranulocytosis was revealed against the background of constant intake of NSAIDs (Aertal, Diclofenac, ibuprofen) for 3 years for joint pain. Surgical treatment was performed and antibiotic therapy was prescribed. Against the background of Filgrastim therapy, a positive dynamics of peripheral blood parameters was noted. The use of granulocyte colony stimulating factors (G-CSF) significantly reduces the severity of the disease, reduces the duration of hospitalization and mortality in patients with drug-associated agranulocytosis.

  • Modern approaches to the treatment of anemia of malignant neoplasms

    by A. A. Pecherskikh, T. V. Parfenova, T. V. Pinchuk, N. V. Orlova, N. D. Karseladze, А. O. Bolshepaeva, О. A. Parfenova

    Anemia in patients with cancer is a common concomitant condition. The development of anemia in cancer has a multifactorial pathogenesis, including inflammation, metastasis of solid tumors to the bone marrow and displacement of normal hematopoiesis sprouts in the bone marrow by tumor cells in hemoblastosis, myelosuppression against the background of chemo/radiation therapy, nutritional insufficiency due to anorexia, etc. Anemia in cancer patients reduces the quality of life, the response to antitumor therapy, increases the risk of tumor progression and is an independent factor negatively affecting survival. The article discusses the tactics of managing patients with anemia in accordance with the Clinical recommendations of the Ministry of Health of the Russian Federation “Anemia in malignant neoplasms” and “Management of CancerAssociated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update”. The results of clinical studies are presented, which indicate the effectiveness of the use of erythropoiesis-stimulating drugs (including epoetin alpha) in oncological practice, which reduce the need for hemotransfusions and increase hemoglobin levels in patients with anemia against the background of antitumor chemotherapy.


  • Long-term effects of radiation therapy in outpatient practice

    by N. D. Karseladze, O. A. Tiganova, L. I. Ilyenko, N. V. Orlova, S. Z. Danelyan

    Moscow multidisciplinary clinical center «Kommunarka», Moscow, Russia SUMMARY Radiation therapy is one of the main methods of treating malignant neoplasms. Along with high efficiency, radiation therapy leads to complications in the early and late period. General practitioners and therapists are insufficiently familiar with long-term radiation-induced complications. The article presents data on the pathogenesis, clinical manifestations, diagnosis and treatment of radiation lesions of the bone system, lungs, myocardium, gastrointestinal tract, genitourinary system, hematopoiesis system, as well as chronic pain syndrome. The symptoms of late complications of radiation therapy are nonspecific and similar to the symptoms of somatic diseases. Knowledge of the clinical manifestations of radiation-induced complications in the long term allows timely diagnosis and treatment.

  • Anemia of chronic diseases

    by N. V. Orlova, N. D. Karseladze

    Anemia of chronic diseases is one of the most common diseases and has a significant impact on prognosis and mortality. The article discusses the relevance, pathogenesis, clinical manifestations, laboratory diagnostics, and treatment of anemia of chronic diseases. The treatment of anemia depends on the severity and the disease of which it is a complication. Anemia is considered in oncological diseases, chronic kidney disease, chronic heart failure, cirrhosis of the liver, celiac disease, etc. Therapy aimed at replenishing iron deficiency includes transfusion of erythrocyte mass, erythropoietin stimulants, iron-containing drugs. According to the literature review, information is provided on the peculiarities of managing patients with anemia in various chronic diseases, an overview of the modern approach to ferrotherapy and its complications is given. Information is provided on a new form of oral iron – Sucrosomal iron (SiderAL Forte), which is well tolerated and has high bioavailability. A review of clinical studies confirming the efficacy and safety of oral Sucrosomal iron is presented.